Nonlinear relationship between circulating natural killer cell count and 1-year relapse rates in myasthenia gravis: a retrospective cohort study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Higher natural killer (NK) cell counts may protect against myasthenia gravis (MG) relapse. This suggests NK cells could be a biomarker for predicting MG recurrence risk.
Area Of Science
- Immunology
- Neurology
- Epidemiology
Background
- Myasthenia gravis (MG) has a high relapse rate, posing a clinical challenge.
- Identifying predictive factors for MG recurrence is crucial for effective management.
- Circulating natural killer (NK) cell levels are explored as potential predictors.
Purpose Of The Study
- To investigate the association between circulating NK cell counts and MG recurrence risk.
- To determine if NK cell levels can serve as a biomarker for MG relapse.
- To explore potential immunoregulatory roles of NK cells in MG.
Main Methods
- Retrospective cohort study of 265 MG patients.
- Data collected from electronic medical records (March 2015-March 2022).
- Analysis of circulating NK cell count as the exposure variable and 1-year MG recurrence rate as the primary outcome.
Main Results
- A non-linear relationship was found between NK cell count and MG recurrence.
- Lower recurrence risk was observed with NK cell counts above an inflection point of 5.38 (RR: 0.23).
- No significant association was found for NK cell proportion (RR: 0.84).
Conclusions
- Peripheral NK cell count may be associated with MG recurrence risk.
- Specific NK cell count ranges may indicate an immunoregulatory protective effect.
- Findings suggest potential for personalized MG treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...